BiotechTube

Quemliclustat + Placebo + Nab-paclitaxel + Gemcitabine

Phase 3Active
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Pancreatic Ductal Adenocarcinoma

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Trial Timeline

Dec 13, 2024 → Nov 30, 2030

NCT ID
NCT06608927

About Quemliclustat + Placebo + Nab-paclitaxel + Gemcitabine

Quemliclustat + Placebo + Nab-paclitaxel + Gemcitabine is a phase 3 stage product being developed by Arcus Biosciences for Metastatic Pancreatic Ductal Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT06608927. Target conditions include Metastatic Pancreatic Ductal Adenocarcinoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06608927Phase 3Active

Competing Products

20 competing products in Metastatic Pancreatic Ductal Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
AbemaciclibEli LillyPre-clinical
23
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
77
SYNB1891 + AtezolizumabSynlogicPhase 1
25
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
77
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
41
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Induction therapyChugai PharmaceuticalPhase 2
52
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
52
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
52
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
GC33Chugai PharmaceuticalPhase 1
33
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
DS9051bDaiichi SankyoPhase 1
33

Other Products from Arcus Biosciences

Casdatifan + Cabozantinib + PlaceboPhase 3
72
Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)Phase 2
47
Etrumadenant (AB928) + FOLFOX regimen + Zimberelimab (AB122)Phase 2
47
Zimberelimab + DomvanalimabPhase 2
47
Zimberelimab + Domvanalimab + EtrumadenantPhase 2
47